Related Experiment Videos
Implications of leukoregulin to autologous tumor-specific human T-cell populations
C L Slingluff1, H F Seigler, T L Darrow
1Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Insights
Leukoregulin (LR) enhances cytotoxic T-lymphocyte (CTL) activity against melanoma and normal cells in vitro. This hormone increases target cell sensitivity, offering potential therapeutic applications for cancer immunotherapy.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Leukoregulin (LR) is known to enhance natural killer (NK) cell activity.
- Interactions between cellular and humoral immunity are complex.
- The role of LR in cytotoxic T-lymphocyte (CTL) function was previously unexplored.
Purpose of the Study:
- To investigate the interaction between Leukoregulin (LR) and human cytotoxic T-lymphocytes (CTLs).
- To determine if LR can modulate CTL-mediated cytotoxicity against various target cells.
- To explore the potential therapeutic implications of LR in cancer immunity.
Main Methods:
- Utilized chromium release assays to measure CTL cytotoxicity.
- Co-cultured T-cell populations with autologous melanoma, allogeneic melanoma, K562 cells, and autologous peripheral blood lymphocytes (PBLs).
- Pretreated target cells with LR and assessed dose-dependent effects and inhibition patterns.
Main Results:
- LR pretreatment significantly increased CTL-mediated lysis of allogeneic melanoma and K562 cells.
- LR also induced lysis of autologous PBLs by specific CTLs, a dose-dependent effect.
- LR did not enhance the lysis of autologous melanoma by specific CTLs, suggesting a non-MHC restricted mechanism.
Conclusions:
- Leukoregulin (LR) can mediate lysis of melanoma, NK targets, and normal PBLs by tumor-specific CTLs.
- The observed LR effects are dose-dependent and non-major histocompatibility complex-restricted.
- While LR may not play a significant role in normal CTL physiology, its in vitro effects show experimental and therapeutic promise.
Abstract:
Interactions between the cellular and humoral compartments of the human immune system are well documented. Leukoregulin (LR) is a hormone with the ability to upregulate the natural killer (NK) phenomenon by increasing target cell sensitivity to NK lymphocyte cytotoxicity. In the present report, the interactions between LR and human cytotoxic T-lymphocytes (CTLs) are described. Two cultured T-cell populations are specifically cytotoxic for autologous human melanoma and fail to lyse allogeneic melanoma, K562, or autologous peripheral blood lymphocytes (PBLs) in 4 h chromium release assays. Pretreating allogeneic melanoma or K562 with LR resulted in 19-67% lysis at an effector:target (E:T) ratio of 5:1, while no more than 10% lysis was observed without LR. Autologous PBLs were also subject to lysis when pretreated with LR (50% at an E:T of 40:1 with LR, and 2% without LR). The observed effect was dose-related and was most effectively inhibited by autologous cold targets, but persisted in the presence of antibody to human lymphocyte antigen class I antigens (w6/32). Lysis of autologous melanoma was not increased by pretreatment with LR. LR appears to mediate lysis of melanoma, NK targets, and normal PBLs by tumor specific CTLs. The effect is dose-related and non-major histocompatibility complex-restricted. The data do not support a significant role for LR in the normal physiology of human CTLs, but the striking effects in vitro may prove to be experimentally or therapeutically useful.